Reappraisal of FibroTest for Liver Injury Biomarker
Author Information
Author(s): Poynard Thierry, Munteanu Mona, Deckmyn Olivier, Ngo Yen, Drane Fabienne, Messous Djamila, Castille Jean Marie, Housset Chantal, Ratziu Vlad, Imbert-Bismut Françoise
Primary Institution: APHP UPMC Paris Liver Center, Paris, France
Hypothesis
What is the applicability rate of the FibroTest and how can false positives/negatives be reduced?
Conclusion
The mean applicability rate of FibroTest was 99.03%, with independent factors associated with high risk of false positives/negatives identified.
Supporting Evidence
- The prevalence of RFPN was 0.52% in blood donors and 0.51% in healthy volunteers.
- Independent factors associated with high RFPN included HIV center and sub-Saharan origin.
- Low haptoglobin was the most frequent cause of RFPN across all populations.
Takeaway
FibroTest is a blood test that helps check for liver damage, and it works really well most of the time, but some people might get wrong results.
Methodology
Four populations were studied, including blood donors, healthy volunteers, and patients from a tertiary care center, with analytical procedures reviewed for accuracy.
Potential Biases
Potential biases include the reliance on laboratory procedures and the characteristics of the populations studied.
Limitations
There is no perfect reference test for defining false positives/negatives in large populations.
Participant Demographics
The study included blood donors, healthy volunteers, and patients from various demographics, including those from HIV centers and sub-Saharan origins.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 0.17-1.22
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website